DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 649, Issue 1-2, 2008, Pages 213-220

  Friedrisch, João Ricardo ^a   Prá, Daniel ^b   Maluf, Sharbel Weidner ^a,c   Bittar, Christina Matzembacher ^a   Mergener, Michelle ^c   Pollo, Tiago ^c   Kayser, Michele ^c   da Silva, Maria Aparecida Lima ^a   Henriques, João Antonio Pêgas ^b   da Rocha Silla, Lucia Mariano ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDADE FEEVALE   (Brazil)

Author keywords

Comet assay; Genotoxicity; Hydroxyurea; Sickle cell disease

Indexed keywords

DNA; HYDROXYUREA;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD; CLINICAL ARTICLE; COMET ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; FEMALE; GENDER; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; PH; PRIORITY JOURNAL; SAMPLE; SICKLE CELL ANEMIA; SMOKING; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CHILD, PRESCHOOL; COMET ASSAY; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYUREA; LEUKOCYTES; MALE; MIDDLE AGED;

EID: 37049008636     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2007.09.005     Document Type: Article

References (48)

1. Steinberg M.H. Management of sickle cell disease. N. Engl. J. Med. 340 (1999) 1021-1030
2. Yarbro J.W. Mechanism of action of hydroxyurea. Semin. Oncol. 19 (1992) 1-10
3. De Vita V.T., Hellman S., and Rosenberg A.S. Cancer: Principles and Practice of Oncology. 5th ed. (1997), Lippincott Raven Publishers, New York
4. Mayhew C.N., Phillips J.D., Greenberg R.N., Birch N.J., Elford H.L., and Gallicchio V.S. In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity. Stem Cells 17 (1999) 345-356
5. de Montalembert M. Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin. Pathol. Biol. (Paris) 47 (1999) 55-58
6. de Melo E.J., Mayerhoffer R.O., and de Souza W. Hydroxyurea inhibits intracellular Toxoplasma gondii multiplication. FEMS Microbiol. Lett. 185 (2000) 79-82
7. Gebhart E. Sister chromatid exchange (SCE) and structural chromosome aberration in mutagenicity testing. Hum. Genet. 58 (1981) 235-254
8. Oppenheim J.J., and Fishbein W.N. Induction of chromosome breaks in cultured normal human leukocytes by potassium arsenite, hydroxyurea and related compounds. Cancer Res. 25 (1965) 980-985
9. Murphy M.L., and Chaube S. Preliminary survey of hydroxyurea (Nsc-32065) as a teratogen. Cancer Chemother. Rep. 40 (1964) 1-7
10. Aliverti V., Bonanomi L., and Giavini E. Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administrations to pregnant rats. Arch. Toxicol. Suppl. 4 (1980) 239-247
11. Ziegler-Skylakakis K., Schwarz L.R., and Andrae U. Microsome- and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells. Mutat. Res. 152 (1985) 225-231
12. Griffith K.M. Hydroxyurea (Nsc-32065): results of a phase I study. Cancer Chemother. Rep. 40 (1964) 33-36
13. Sedlacek S.M., Curtis J.L., Weintraub J., and Levin J. Essential thrombocythemia and leukemic transformation. Medicine (Baltimore) 65 (1986) 353-364
14. Lofvenberg E., Nordenson I., and Wahlin A. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet. Cytogenet. 49 (1990) 57-67
15. Furgerson J.L., Vukelja S.J., Baker W.J., and O'Rourke T.J. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am. J. Hematol. 51 (1996) 137-140
16. Najean Y., and Rain J.D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 90 (1997) 3370-3377
17. Fruchtman S.M., Mack K., Kaplan M.E., Peterson P., Berk P.D., and Wasserman L.R. From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin. Hematol. 34 (1997) 17-23
18. Charache S., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N. Engl. J. Med. 332 (1995) 1317-1322
19. Ohene-Frempong K., and Smith-Whitley K. Use of hydroxyurea in children with sickle cell disease: what comes next?. Semin. Hematol. 34 (1997) 30-41
20. Rogers Z.R. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Semin. Hematol. 34 (1997) 42-47
21. Kinney T.R., Helms R.W., O'Branski E.E., Ohene-Frempong K., Wang W., Daeschner C., Vichinsky E., Redding-Lallinger R., Gee B., Platt O.S., and Ware R.E. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94 (1999) 1550-1554
22. Ferster A., Tahriri P., Vermylen C., Sturbois G., Corazza F., Fondu P., Devalck C., Dresse M.F., Feremans W., Hunninck K., Toppet M., Philippet P., Van Geet C., and Sariban E. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 97 (2001) 3628-3632
23. Koren A., Segal-Kupershmit D., Zalman L., Levin C., Hana M.A., Dina A.L., and Attias D. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Pediatr. Hematol. Oncol. 16 (1999) 221-232
24. Steinberg M.H., Barton F., Castro O., Koshy M., Eckman J., and Terrin M. Risks and benefits of hydroxyurea (HU) in adult sickle cell anemia: effects at 6- to 7- years [abstract]. Blood 94 (1999) 644a
25. Bakanay S.M., Dainer E., Clair B., Adekile A., Daitch L., Wells L., Holley L., Smith D., and Kutlar A. Mortality in sickle cell patients on hydroxyurea therapy. Blood 105 (2005) 545-547
26. Njoku O.S., Johnson S.B., Kulkarni A.G., and Mba E.C. Acute lymphoblastic leukaemia in a Nigerian adult with sickle cell anaemia. Central Afr. J. Med. 34 (1988) 158-160
27. Al-Jam'a A.H., Al-Dabbous I.A., Al-Khatti A.A., and Esan F.G. Are we underestimating the leukemogenic risk of hydroxyurea. Saudi Med. J. 23 (2002) 1411-1413
28. Rauch A., Borromeo M., Ghafoor A., Khoyratty B., and Maheshwari J. Leukaemogenis of hydroxyurea in the treatment of sickle cell anemia [abstract]. Blood 94 (1999) 415a
29. Wilson S. Acute leukaemia in a patient with sickle cell anemia. Ann. Intern. Med. 133 (2000) 925-926
30. Singh N., McCoy M., Tice R., and Schneider E. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175 (1988) 184-191
31. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.C., and Sasaki Y.F. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35 (2000) 206-221
32. Hartmann A., Agurell E., Beevers C., Brendler-Schwaab S., Burlinson B., Clay P., Collins A., Smith A., Speit G., Thybaud V., and Tice R.R. 4th International Comet Assay Workshop. Recommendations for conducting the in vivo alkaline Comet assay. Mutagenesis 18 (2003) 45-51
33. Nadin S., Vargas-Roig L., and Ciocca D. A silver staining method for single-cell gel assay. J. Histochem. Cytochem. 49 (2001) 1183-1186
34. Maluf S.W., and Erdtmann B. Follow-up study of the genetic damage in lymphocytes of pharmacists and nurses handling antineoplastic drugs evaluated by cytokinesis-block micronuclei analysis and single cell gel electrophoresis assay. Mutat. Res. 471 (2000) 21-27
35. Li J.C., and Kaminskas E. Progressive formation of DNA lesions in cultured Ehrlich ascites tumor cells treated with hydroxyurea. Cancer Res. 47 (1987) 2755-2758
36. Kumar S., and Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. Toxicol. Lett. 157 (2005) 175
37. Anderson D., Yardley-Jones A., Vives-Bauza C., Chua-Anusorn W., Cole C., and Webb J. Effect of iron salts, haemosiderins, and chelating agents on the lymphocytes of a thalassaemia patient without chelation therapy as measured in the comet assay. Teratog. Carcinog. Mutagen. 20 (2000) 251-264
38. Khayat A.S., Guimaraes A.C., Cardoso P.C., de Lima P.D., Bahia M.O., Antunes L.M., and Burbano R.R. Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease. Genet. Mol. Biol. 27 (2004) 115-117
39. Khayat A.S., Antunes L.M., Guimaraes A.C., Bahia M.O., Lemos J.A., Cabral I.R., Lima P.D., Amorim M.I., Cardoso P.C., Smith M.A., Santos R.A., and Burbano R.R. Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea. Clin. Exp. Med. 6 (2006) 33-37
40. de Lima P.D., Cardoso P.C., Khayat A.S., Bahia M.O., and Burbano R.R. Evaluation of the mutagenic activity of hydroxyurea on the G1-S-G2 phases of the cell cycle: an in vitro study. Genet. Mol. Res. 2 (2003) 328-333
41. Neri M., Ugolini D., Bonassi S., Fucic A., Holland N., Knudsen L.E., Sram R.J., Ceppi M., Bocchini V., and Merlo D.F. Children's exposure to environmental pollutants and biomarkers of genetic damage. II. Results of a comprehensive literature search and meta-analysis. Mutat. Res. 612 (2006) 14-39
42. Speit G., and Hartmann A. The contribution of excision repair to the DNA effects seen in the alkaline single cell gel test (comet assay). Mutagenesis 10 (1995) 555-559
43. Doria G., and Frasca D. Age-related changes of DNA damage recognition and repair capacity in cells of the immune system. Mech. Ageing Dev. 122 (2001) 985-998
44. Hazane F., Sauvaigo S., Douki T., Favier A., and Beani J.C. Age-dependent DNA repair and cell cycle distribution of human skin fibroblasts in response to UVA irradiation. J. Photochem. Photobiol. B 82 (2006) 214-223
45. Jang Y., Kim O.Y., Ryu H.J., Kim J.Y., Song S.H., Ordovas J.M., and Lee J.H. Visceral fat accumulation determines postprandial lipemic response, lipid peroxidation, DNA damage, and endothelial dysfunction in nonobese Korean men. J. Lipid Res. 44 (2003) 2356-2364
46. Smith T.R., Miller M.S., Lohman K.K., Case L.D., and Hu J.J. DNA damage and breast cancer risk. Carcinogenesis 24 (2003) 883-889
47. Hofer T., Karlsson H.L., and Moller L. DNA oxidative damage and strand breaks in young healthy individuals: a gender difference and the role of life style factors. Free Radic. Res. 40 (2006) 707-714
48. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation, World Health Organ Tech Rep Ser. 894, i-xii (2000) 1-253.